[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-centrifugal-cicatricial-alopecia-ccca\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-centrifugal-cicatricial-alopecia-ccca":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100649374","phase-2-tirzepatide-for-treatment-of-ccca-100649374",false,"NCT07734870","Tirzepatide for Treatment of CCCA","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Clinical and\u002For biopsy-confirmed diagnosis of central centrifugal cicatricial alopecia (CCCA).\n* Active CCCA, defined as a C-CAT disease activity score greater than 1.\n* No treatment for CCCA during the 6 weeks before enrollment.\n* Able and willing to complete the study and follow all study procedures.\n* Managed by a Johns Hopkins dermatologist throughout the study.\n\nExclusion Criteria:\n\n* Currently taking an oral or systemic blood glucose-lowering medication.\n* Currently taking another medication for weight loss.\n* Hemoglobin A1C below 5.4%.\n* Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score below 2.\n* Body mass index below 19 kg\u002Fm².\n* Pregnant, breastfeeding, or planning a pregnancy.\n* Personal or family history of medullary thyroid cancer.\n* Personal or family history of multiple endocrine neoplasia type 2.\n* History of chronic kidney disease.\n* History of pancreatitis.\n* History of diabetic retinopathy.\n* Severe gastrointestinal disease.\n* Recent or planned major surgery.\n* Type 1 diabetes.\n* Any other contraindication to tirzepatide.\n* History of keloids or hypertrophic scarring.\n* History of poor wound healing.\n* History of a blood-clotting disorder.\n* Allergy to lidocaine or epinephrine.\n* Known sensitivity to local numbing medication.\n* Any significant medical condition that the investigator believes would make participation unsafe or prevent completion of the study.","ALL","18 Years","80 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults. The main questions it aims to answer are:\n\n* Does tirzepatide improve the symptoms and signs of active CCCA?\n* Does tirzepatide change the activity of genes in the scalp, especially genes related to scarring?\n* Does tirzepatide promote hair regrowth?\n\nParticipants will:\n\n* Inject tirzepatide once a week for 12 months.\n* Visit the clinic for scalp examinations, photographs, and other health assessments.\n* Have scalp biopsies at the beginning of the study and after 6 months of treatment.\n* Have blood tests and other safety monitoring during the study.\n\nThere is no separate comparison group. Researchers will compare each participant's results during treatment with the participant's results at the beginning of the study.",[26],"Central Centrifugal Cicatricial Alopecia (CCCA)",[28,29,30,31,32,33,34,35],"Scarring alopecia","Hair loss","Hair regrowth","Scalp fibrosis","Tirzepatide","Metabolic dysfunction","Insulin Resistance","Gene expression","NOT_YET_RECRUITING","2026-08-11",{"date":39,"type":40},"2026-08-12","ACTUAL",{"date":42,"type":20},"2026-09-15",{"date":44,"type":20},"2028-05-25",{"name":46,"class":47},"Johns Hopkins University","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":16,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100378467","phase-4-treatment-results-for-patients-with-central-centrifugal-cicatricial-alopecia-ccca-a-multicenter-prospective-study-100378467","NCT04207931","Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study","CCCA","Inclusion Criteria:\n\n* African-American women, ages 18-60 years old\n* with a clinical diagnosis and biopsy-proven CCCA, with Central Scalp Alopecia Scale severity 1 through 4 will be included in this study\n* These subjects will be seen and treated in Wake Forest Baptist Health Dermatology Outpatient Clinic\n\nExclusion Criteria:\n\n* Patients with other forms of hair loss in addition to CCCA will be excluded\n* Other patients to be excluded are those with other forms of inflammatory scalp disease (with the exception of mild seborrheic dermatitis)\n* patients who have had topical treatment for CCCA within the past 4 months (including topical steroids, topical minoxidil, or any other topical hair regrowth medication)\n* patients who have been on a long-term oral antibiotics for hair loss within the past year\n* patients who have undergone more than two rounds of intralesional steroid injections to the scalp in the past one year.","FEMALE","60 Years",{"count":58,"type":20},250,[60],"PHASE4","The objective of this study is to examine photos of CCCA patients taken before and after treatment to compare treatment outcomes between different treatment groups",[26],[64,29,65,66,67],"alopecia","Female hair loss","Minoxidil","Topical Steroid","RECRUITING","2026-03-30",{"date":71,"type":40},"2026-03-31",{"date":73,"type":40},"2018-04-30",{"date":75,"type":20},"2027-03",{"name":77,"class":47},"Wake Forest University Health Sciences",1]